Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
144 participants
INTERVENTIONAL
2018-02-05
2022-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy, Safety and Efficiency Study of CARTO® 3 System Guided THERMOCOOL® Catheter Ablation Versus Fluoroscopy Guided Ablation With the Pulmonary Vein Ablation Catheter® (PVAC®)
NCT01116557
Comparison of Operator-guided and Automatic Algorithm-guided Atrial Fibrillation Ablation
NCT02476227
CARTO® 3 System and Real Time Intracardiac Ultrasound
NCT01716663
REVOLUTION (WFCC-133) - Treatment of Paroxysmal Atrial Fibrillation
NCT01353586
Clinical Investigation of the VytronUS Ablation System for Treatment of Paroxysmal Atrial Fibrillation
NCT03639597
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Aim of the study To evaluate the additional benefit of PASO template matching on PVC ablation procedure with regard to procedural parameters and outcome when compared with conventional pace mapping.
Hypothesis PASO guidance during PVC / VT ablation has a significant impact on outcome after catheter ablation of idiopathic PVC / VT.
Study design This study is planned as a two-center trial. All patients presenting for de novo ablation of idiopathic ventricular arrhythmia will be included and randomized in a 1:1 fashion in this open-label, two-center, randomized controlled trial.
In patients randomized to the PASO / intervention group pacemapping will be guided by automated template matching of the PASO module of CARTO3.
In patients randomized to the conventional / control group conventional pacemapping will be employed.
A 3D electroanatomic geometry including activation mapping will be acquired in all patients using CARTO3. Sedation, catheters and monitoring during and after CA, will not differ from standard clinical practice and will be the same for both groups.
Follow-up after 3 and 12 months will assess PVC burden by Holter ECG, symptoms through a standardized questionnaire and LV function by TTE
Duration and study size Based on prior findings ("Impact of Automated Template Matching during PVC Ablation: Results from a Randomized Controlled Trial" Lüker et al. ESC 2014 poster presentation) 144 pts have to be randomized to detect a significant difference with respect to ablation success at follow-up (alpha 0.05, power 80%).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
conventional pace mapping
Conventional PVC pace mapping without visual guidance of PASO
Conventional Pacemapping
without visualisation in 3D mapping
PASO pace mapping
PASO pace mapping with visualisation in CARTO3
PASO Pacemapping
Using the PASO pacemapping visualisation module of CARTO3
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Conventional Pacemapping
without visualisation in 3D mapping
PASO Pacemapping
Using the PASO pacemapping visualisation module of CARTO3
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed, written consent
* ventricular arrhythmia (PVC or VT) with indication for CA
Exclusion Criteria
* Polymorphic PVC / VT
* ongoing myocardial ischaemia
* pregnancy
* valve replacement that prevents access to the suspected site of PVC origin
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biosense Webster, Inc.
INDUSTRY
Universitätsklinikum Köln
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Cologne
Cologne, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UKK-PASTPVC-2018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.